A pilot programme at Christchurch Hospital, which created a specialist intravenous team for patients with difficult intravenous access, has been dropped, despite showing positive results and financial ...
Dogwood Therapeutics secures exclusive worldwide, royalty free license to develop and commercialize Serpin Pharma’s IV formulation, SP16 to treat cancer related pain: Atlanta Tu ...
AUSTIN (KXAN) – A new NICU center at Baylor Scott & White in Round Rock is helping moms bond with their newborns sooner.
Chronic pain and nerve problems can be life-changing. People with peripheral neuropathy often experience burning, tingling ...
A first-in-class LRP1 agonist, SP16 phase 1b Chemotherapy Induced Neuropathy (CIPN) Study fully funded by the National Cancer ...
Shares of US clinical-stage biotech Dogwood Therapeutics soared a massive 43% to $7.91 yesterday, on the news it has secured ...
Waiving the requirement for bioequivalence (BE) and Phase III clinical trials, the Subject Expert Committee (SEC) functioning ...
Researchers assessed the safety and efficacy of combining glofitamab with R-CHOP or Pola-R-CHP among patients with high-risk LBCL aged 65 years or younger.
Investing.com -- Dogwood Therapeutics Inc (NASDAQ:DWTX) stock surged 40.5% on Monday after the clinical-stage biotechnology company announced it had secured a royalty-free, global license to develop ...
Dogwood Therapeutics ( ($DWTX) ) has shared an announcement. On September 29, 2025, Dogwood Therapeutics entered into an exclusive licensing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback